论文部分内容阅读
中俄合资的北京双原同位素技术有限公司成立10年来,年销售额已达千万元,利润百万元,并逐年以20％的速度递增,成为具有一定规模和实力的生产同位素放射源、制剂的优秀企业。这是记者从庆祝北京双原同位素技术有限公司成立十周年大会上获得的消息。北京双原同位素技术有限公司(简称双原公司),1992年由中国原子能院和俄罗斯联邦原子反应堆院合资建立,是中核集团公司的第一家中外合资企业。十年来,中俄双方真诚合作,充分利用各自的优势,相互信任,相互理解,公司不断发展壮大,很快进入了快速发展期,并取得了不凡的业绩。据了解,双原公司目前开发的主要
Sino-Russian joint venture Beijing Double Original isotope Technology Co., Ltd. was established 10 years ago, with annual sales of 10 million yuan, profits million yuan, and 20% year by year the rate of increase has become a certain scale and strength of the production of isotope radioactive sources, Preparation of outstanding enterprises. This is the news from the press conference that celebrated the 10th anniversary of the founding of Beijing Shuangyuan Isotope Technology Co., Ltd. Beijing Shuangyuan Isotope Technology Co., Ltd. (Shuangyuan Co., Ltd.) was established as a joint venture between the China Institute of Atomic Energy and the Russian Federation Atomic Reactor in 1992. It is the first Sino-foreign joint venture of CNNC Corporation. Over the past decade, both China and Russia have made sincere cooperation and take full advantage of their respective advantages, mutual trust and mutual understanding. The company has continuously grown stronger and has quickly entered a phase of rapid development and achieved remarkable results. It is understood that the original development of the original double-main